Endo Health Solutions Pleads Guilty to Marketing Opioid as Abuse Deterrent Without Supporting Data

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Endo Health Solutions Pleads Guilty to Marketing Opioid as Abuse Deterrent Without Supporting Data

$1.536 Billion Criminal Penalty Is Part of Global Settlement of Alleged Opioid Promotion Violations

Dennis Tosh

April 23, 2024 at 04:48 PM EST

A U.S. subsidiary of an international pharmaceutical company has pleaded guilty to a charge of introducing misbranded drugs into interstate commerce, acknowledging that it claimed that an opioid drug was tamper and crush resistant and therefore abuse deterrent without clinical data substantiating the claims (United States v. Endo Health Solutions Inc., No. 2:24-cr-20159-LVP-AP... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Endo Health Solutions Pleads Guilty to Marketing Opioid as Abuse Deterrent Without Supporting Data

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT